Clinical inquiries. What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer?

Recombinant human thyrotropin (rhTSH)-stimulated serum thyroglobulin (Tg) level alone is sufficient to monitor for recurrent disease in low-risk patients with a history of differentiated thyroid cancer (DTC). Low-risk patients are defined as patients who have undergone total thyroidectomy and radioactive iodine (I(131)) remnant ablation therapy and show no clinical evidence of recurrent disease.